Minocycline in Severe Cerebral Amyloid Angiopathy: A Single‐Center Cohort Study
Journal of the American Heart Association · 20.02.2024 · 13 (4)
DOI: 10.1161/jaha.123.033464 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.02.2024. Verfasst von Francesco Bax und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hemorrhagic Stroke Research Program, J Philip Kistler Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical Sc…. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Minocycline. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Evidence from animal studies suggests that minocycline may reduce lobar intracerebral hemorrhage (ICH) recurrence in cerebral amyloid angiopathy, possibly by inhibiting perivascular extracellular matrix degradation in cerebral small vessels. There is currently no evidence of its safety or efficacy in humans with cerebral amyloid angiopathy. Methods and Results To provide preliminary data to support future studies of minocycline's efficacy, the authors performed a retrospective single‐center cohort study to assess the incidence of recurrent ICH in patients with an aggressive clinical course of probable cerebral amyloid angiopathy who had been prescribed minocycline off‐label via shared decision‐making. Crude incidence rate ratios were calculated to compare incidence rates before versus after treatment. Sixteen patients (mean age at minocycline initiation, 66.3±3.5 years; women 62.5%; median of 3 lobar ICHs [range, 1–6]) were initiated on minocycline and followed for a median of 12.4 months (range, 1.8–61.4 months). Adverse events were reported in 4 of 16 patients (gastroenteric, n=3; dizziness, n=1) and were considered mild. ICH incidence sharply increased the year before minocycline initiation compared with the preceding years (2.18 [95% CI, 1.50–3.07] versus 0.40 [95% CI, 0.25–0.60] events per patient‐year) and fell to 0.46 (95% CI, 0.23–0.83) events per patient‐year afterwards. Incidence rate ratios of recurrent ICH after minocycline was lower (0.21 [95% CI, 0.11–0.42], P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hemorrhagic Stroke Research Program, J Philip Kistler Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School 175 Cambridge Street Boston 02114 MA USA.
ORCID-Profile: Francesco Bax, Andrew Warren, Hilde van den Brink, Susanne J van Veluw, Mariel G Kozberg, Steven M Greenberg
Zitieren
APA
Bax, F., Warren, A., Fouks, A. A., van den Brink, H., van Veluw, S. J., Kozberg, M. G., & Greenberg, S. M. (2024). Minocycline in Severe Cerebral Amyloid Angiopathy: A Single‐Center Cohort Study. Journal of the American Heart Association, 13(4). https://doi.org/10.1161/jaha.123.033464
Vancouver
Bax F, Warren A, Fouks AA, van den Brink H, van Veluw SJ, Kozberg MG, et al. Minocycline in Severe Cerebral Amyloid Angiopathy: A Single‐Center Cohort Study. Journal of the American Heart Association. 2024;13(4). doi:10.1161/jaha.123.033464
BibTeX
@article{Bax2024,
author = {Bax, Francesco and Warren, Andrew and Fouks, Avia Abramovitz and van den Brink, Hilde and van Veluw, Susanne J and Kozberg, Mariel G and Greenberg, Steven M},
title = {Minocycline in Severe Cerebral Amyloid Angiopathy: A Single‐Center Cohort Study},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {4},
doi = {10.1161/jaha.123.033464}
}
EUVIMED